Most-Read Oncology Articles of 2021
The most-read oncology news of 2021 included the FDA’s review of accelerated approvals, COVID-19 vaccine effectiveness in patients with blood cancer, and more.
Two Approvals in Urothelial Cancer Survive FDA Panel Scrutiny
As hearings of the FDA panel have shown, once a drug is approved and in clinical guidelines, pulling it from the market is not so simple, even if later trials do not confirm phase 2 results.
FDA Update: Merck Action on Keytruda Gastric Cancer Indication Tops Busy Week
Merck will withdraw Keytruda's advanced gastric indication after an FDA panel vote, a drug with supply problems gets a new indication, NDAs for an HIV therapy, and other news.
Antibodies Go Missing After COVID-19 Vaccination in Some Blood Cancer Patients
Lack of antibodies from vaccination mainly affects patients with B cell cancers. Experts say antibodies are just one piece of the puzzle and that other aspects of the immune system fend off serious cases of COVID-19.
Feasibility Study Shows Mobile Devices Help Patients Communicate Cancer Treatment Effects
Mobile devices for patients to report symptoms associated with immune checkpoint inhibitors address an unmet need.
ASCO 2021: Lumakras, First Approved KRAS-targeting Cancer Drug, Looks Promising
The FDA approved Amgen’s Lumakras (sotorasib) last week, the first drug targeting KRAS-mutated cancer to get the agency’s OK. But the clinical and commercial future of the drug is uncertain.
